Biotech Calendar: Key Dates for November

BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for November:

Oct. 30-Nov. 4
The American Association for the Study of Liver Disease convenes in Boston. This is the most important meeting for hepatitis C drug research held on the U.S. every year. Stocks to watch include Vertex Pharmaceuticals(VRTX Quote), InterMune(ITMN Quote), Pharmasset(VRUS Quote), Schering-Plough(SGP Quote) and Merck(MRK Quote)

Nov. 2
Results from the "Bliss-76" phase III study of Human Genome Sciences'(HGSI Quote) lupus drug Benlysta.

Nov. 3-4
Oppenheimer & Co. Healthcare conference

Nov. 9
FDA approval decision date for Xenoport's(XNPT Quote) XP-13512 in restless leg syndrome. (With GlaxoSmithKline(GSK Quote) as marketing partner.)

Nov. 10
Cephalon(CEPH Quote) R&D Day

Nov. 10-14
Chemotherapy Foundation Meeting

Nov. 13
FDA approval decision date for Cadence Pharmaceuticals'(CADX Quote) Acetavance (IV acetaminophen for hospital use)

Nov. 14-15
FDA approval decision date for Genzyme's(GENZ Quote) Lumizyme for Pompe disease

Nov. 14-18
American Heart Association Scientific Sessions

Nov. 15-19
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Nov. 16
FDA approval decision date for NeurogesX's(NGSX Quote) Qutenza for neuropathic pain

Nov. 17-18
Lazard Capital Management Healthcare Conference

Nov. 20
FDA approval decision date for Human Genome Science's Abthrax for anthrax infection

Important clinical trials with potential data readouts or other biotech events expected in November:

Dendreon(DNDN Quote) resubmission of Provenge to FDA
Expected mid-November

FDA approval decision date for Auxillium Pharmaceuticals'(AUXL Quote) Xiaflex for Dupuytren's Contracture. (With Pfizer(PFE Quote) as marketing partner.)
Expected mid-November

Company: Alkermes(ALKS Quote)
Drug/indication: Vivitrol for opioid dependence
Clinical trial event: Phase III top-line results
Timing: Fourth quarter 2009

Company:Chelsea Therapeutics(CHTP Quote)
Drug/indication: Droxidopa for orthostatic hypotension
Timing: Fourth quarter 2009

Company:Gilead Sciences(GILD Quote)
Drug/indication: Darusentan for resistant hypertension
Timing: Fourth quarter 2009